Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.

Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J and 13 more

Show all authors

McKeown W, O'shea M, Baughman R, Wood K, Haupt M, Kaiser R, Simms H, Warnock D, Summer W, Hintz R, Myers B, Haenftling K, Capra W

Kidney international1 Jun 1999Cited by 173 (Europe PMC)

PMID10354291DOI10.1046/j.1523-1755.1999.00463.xPepBankPUB-10354291

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acute renal failure, rhIGF-I did not change glomerular filtration rate differently from placebo.
In plain wordsIn acute kidney failure, rhIGF-I did not improve kidney filtration more than placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeGlomerular filtration rate change
Study
n = 72
Comparator
Placebo
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Measurements
Mean urinary iothalamate clearance (glomerular filtration rate)
6.4 ml/min
baseline rhIGF-I group (+/- SD 5.9)
Mean urinary iothalamate clearance (glomerular filtration rate)
8.7 ml/min
baseline placebo group (+/- SD 7.2)
Median urinary iothalamate clearance (glomerular filtration rate)
4.3 ml/min
baseline rhIGF-I group
Median urinary iothalamate clearance (glomerular filtration rate)
4.4 ml/min
baseline placebo group
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
Summary
In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 +/- 1037 (887) and 1402 +/- 1183 (1430) ml/24 hr and 6.4 +/- 5.9 (4.3) and 8.7 +/- 7.2 (4.4) ml/min and did not differ between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429101
02HumanRandomized controlled trialEfficacy outcome
In acute renal failure, creatinine clearance changes did not differ between rhIGF-I and placebo.
In plain wordsIn acute kidney failure, creatinine clearance changed similarly with rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeCreatinine clearance change
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429102
03HumanRandomized controlled trialEfficacy outcome
In acute renal failure, daily urine volume changes did not differ between rhIGF-I and placebo.
In plain wordsIn acute kidney failure, daily urine volume changed similarly with rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeDaily urine volume change
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Measurements
Mean urine volume
1116 ml/24 hr
baseline rhIGF-I group (+/- SD 1037)
Mean urine volume
1402 ml/24 hr
baseline placebo group (+/- SD 1183)
Median urine volume
887 ml/24 hr
baseline rhIGF-I group
Median urine volume
1430 ml/24 hr
baseline placebo group
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
Summary
In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 +/- 1037 (887) and 1402 +/- 1183 (1430) ml/24 hr and 6.4 +/- 5.9 (4.3) and 8.7 +/- 7.2 (4.4) ml/min and did not differ between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429103
04HumanRandomized controlled trialEfficacy outcome
In acute renal failure, serum urea nitrogen changes did not differ between rhIGF-I and placebo.
In plain wordsIn acute kidney failure, blood urea nitrogen changed similarly with rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum urea nitrogen change
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429104
05HumanRandomized controlled trialEfficacy outcome
In acute renal failure, serum creatinine changes did not differ between rhIGF-I and placebo.
In plain wordsIn acute kidney failure, blood creatinine changed similarly with rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum creatinine change
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429105
06HumanRandomized controlled trialEfficacy outcome
In acute renal failure, serum albumin changes did not differ between rhIGF-I and placebo.
In plain wordsIn acute kidney failure, blood albumin changed similarly with rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum albumin change
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429106
07HumanRandomized controlled trialEfficacy outcome
In acute renal failure, serum transferrin changes did not differ between rhIGF-I and placebo.
In plain wordsIn acute kidney failure, blood transferrin changed similarly with rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum transferrin change
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429107
08HumanRandomized controlled trialEfficacy outcome
In acute renal failure, 20 rhIGF-I patients and 17 placebo patients underwent dialysis or ultrafiltration.
In plain wordsIn acute kidney failure, 20 rhIGF-I patients and 17 placebo patients needed dialysis or ultrafiltration.
Peptide
IGF-1 (mecasermin)
Outcome
Direction not reportedDialysis or ultrafiltration
Study
n = 72
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Measurements
Patients undergoing dialysis or ultrafiltration
20 patients
rhIGF-I group
Patients undergoing dialysis or ultrafiltration
17 patients
placebo group
Source sentences
Summary
Twenty patients in the rhIGF-I group and 17 placebo-treated patients underwent dialysis or ultrafiltration.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429110
09HumanRandomized controlled trialSafety outcome
In acute renal failure, 12 rhIGF-I patients and 12 placebo patients died within 28 days.
In plain wordsIn acute kidney failure, 12 patients died in each group within 28 days.
Peptide
IGF-1 (mecasermin)
Outcome
Direction not reportedDeaths
Study
n = 72
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Measurements
Deaths within 28 days after onset of treatment
12 patients
rhIGF-I group
Deaths within 28 days after onset of treatment
12 patients
placebo group
Source sentences
Summary
Twelve rhIGF-I-treated patients and 12 placebo-treated patients died during the 28 days after the onset of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429111
10HumanRandomized controlled trialEfficacy outcome
In patients without renal replacement therapy, serum creatinine did not differ significantly between rhIGF-I and placebo.
In plain wordsIn patients without kidney replacement treatment, blood creatinine did not differ significantly between rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum creatinine without renal replacement
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429108
11HumanRandomized controlled trialEfficacy outcome
In patients without renal replacement therapy, serum urea did not differ significantly between rhIGF-I and placebo.
In plain wordsIn patients without kidney replacement treatment, blood urea did not differ significantly between rhIGF-I and placebo.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum urea without renal replacement
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
100 microgram/kg desirable body weight every 12 hours · subcutaneous · up to 14 daysAs given in this study (human).
Source sentences
Summary
In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals.
Summary · context
Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients).
Summary · context
Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days.
Report a problemFND-1035429109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.